Spectral AI, Inc. (NASDAQ:MDAI) Short Interest Down 17.7% in June

Spectral AI, Inc. (NASDAQ:MDAI) was the target of a significant decline in short interest during the month of June. As of June 15th, there was short interest totalling 394,500 shares, a decline of 17.7% from the May 31st total of 479,100 shares. Currently, 5.4% of the company’s stock are sold short. Based on an average trading volume of 288,200 shares, the days-to-cover ratio is presently 1.4 days.

Spectral AI Stock Down 7.2 %

Shares of NASDAQ MDAI traded down $0.14 during midday trading on Tuesday, reaching $1.81. 331,451 shares of the company’s stock were exchanged, compared to its average volume of 1,219,285. Spectral AI has a 52-week low of $1.52 and a 52-week high of $19.50. The business’s fifty day moving average price is $1.69 and its two-hundred day moving average price is $2.07.

Spectral AI (NASDAQ:MDAI) last announced its earnings results on Tuesday, May 7th. The company reported ($0.19) earnings per share (EPS) for the quarter. The firm had revenue of $6.33 million during the quarter.

Institutional Trading of Spectral AI

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Highlander Partners L.P. increased its holdings in Spectral AI by 18.6% in the fourth quarter. Highlander Partners L.P. now owns 900,000 shares of the company’s stock valued at $2,214,000 after buying an additional 141,416 shares during the last quarter. Hsbc Holdings PLC bought a new stake in Spectral AI in the third quarter valued at about $224,000. Murchinson Ltd. bought a new stake in Spectral AI in the first quarter valued at about $85,000. Citigroup Inc. bought a new stake in Spectral AI in the third quarter valued at about $62,000. Finally, Virtu Financial LLC bought a new stake in Spectral AI in the first quarter valued at about $38,000. 67.08% of the stock is owned by institutional investors.

Spectral AI Company Profile

Spectral AI, Inc, an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers.